Dr Herpain discusses the concerns surrounding inotropin use but demonstrates supporting data for the use of levosimendan due to its different pharmacokinetic properties whereby morbidity and mortality are actually reduced, and a marked improvement on glomerular filtration is seen. This footage includes a succinct summary of the benefits of levosimendan and also a Q&A section on levosimendan use in the ICU, cardiac surgery and acute cardiac care.View other expert videos and find out more about the role and potential benefits of levosimendan
Prof. Dr Heringlake explores the need for new therapeutic concepts in high risk CABG patients and the positive effects of preoperative levosimendan in reducing mortality in patients undergoing isolated CABG.
What is known about levosimendan and the kidney? Watch Professor Ricksten as he reviews this question and points out the difference between levosimendan compared to other inotropes.
What makes levosimendan different from other inotropes? Discover the use of levosimendan in different settings, while Dr Herpain explores the benefits of this agent, especially on cardio-renal function.
Are catecholamines safe in critically ill patients? Find out about their negative effects and why it’s time to consider better alternatives.
Prof. Dr Heringlake gives a concise overview of the rationale behind using levosimendan as a first-line agent and runs through the literature suggesting its optimum use. Find out why this drug is not only good for the heart but also good for the kidney.